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Chronic hypertension affects up to 5% of pregnant women in the 
USA.[1] More importantly, its prevalence may be increasing owing to 
increasing obesity, women choosing to become pregnant in the later 
period of child-bearing age and an increasing number of pregnancies 
with comorbidities, such as diabetes and renal disease.[2] 
Chronic hypertension may occur more frequently in black 
population groups than in the white population. It is a risk factor for 
adverse maternal and perinatal outcomes, and 13 - 40% of women 
may develop superimposed pre-eclampsia.[1] This article presents 
data on lessons that may be learnt from maternal death assessments 
and discusses a practical approach to the clinical management of 
chronic hypertension in pregnancy. 
Data of maternal deaths from chronic 
hypertension in 2014 - 2016 in South 
Africa
Chronic hypertension is one of the categories of the hypertensive 
disorders of pregnancy (HDP), the others being gestational 
hypertension, white-coat hypertension and pre-eclampsia, which may 
be de novo or superimposed on chronic hypertension, eclampsia, and 
haemolysis, elevated liver enzymes and low platelet count (HELLP) 
syndrome.[3] Recently, the International Society for the Study of 
Hypertension in Pregnancy suggested that clinicians should be aware 
of two entities, i.e. masked hypertension and transient gestational 
hypertension.[3] Masked hypertension is defined as a normal blood 
pressure (BP) level recorded in a health facility but an elevated BP 
outside such a facility, while transient gestational hypertension 
denotes de novo hypertension and spontaneous resolution during 
pregnancy.[3]
There were 661 maternal deaths due to HDP in South Africa (SA)
in the triennium 2014 - 2016.[4] In 40 (6%) of these deaths, assessors 
ascertained that chronic hypertension was the primary cause of 
death. The clinical characteristics of these deaths are shown in Table 1. 
All patients were >28 years of age and 22 (55%) were >35 years 
old. There were 4 primigravidas between the ages of 28 and 34 years.
Table 2 shows preventable factors and indicates that these were 
mainly related to the conduct of health professionals.
Maternal deaths due to chronic hypertension occurred at all 
levels of healthcare – public sector (district and regional hospitals) 
and private sector. Seven patients were readmitted to hospital after 
delivery; they are particularly prominent owing to the following 
reasons related to their management: early hospital discharge without 
good control of high BP, and failure to recognise that respiratory 
signs in women with chronic hypertension in the postpartum period 
may signify pulmonary oedema or peripartum cardiomyopathy. In a 
proportion of cases, there was failure to recognise the likelihood of 
cardiopulmonary problems, with resultant delay in investigation and 
diagnosis. Therefore, the main problems in clinical management can 
be summarised as follows: (i) failure to identify patients at risk of 
complications; (ii) failure to triage patients or seek specialist advice 
timeously; (iii) delays in transport for referral to a higher level of 
healthcare; and (iv) delays in immediate appropriate treatment of 
high BP. 
Clinical management of chronic 
hypertension in pregnancy 
Chronic hypertension is defined as systolic/diastolic BP >140/90 mmHg, 
documented before pregnancy or before the 20th week of pregnancy 
on at least two occasions at least 4 hours apart.[1] Many women of child-
bearing age only commence antenatal visits or antenatal care during 
the second or third trimester of pregnancy, particularly in low- and 
middle-income countries. Given the physiological changes in the first 
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half of pregnancy, i.e. a decrease in BP owing to vasodilation,[5] high 
BP recorded for the first time in the late second or third trimester is 
usually diagnosed as gestational hypertension. This could be chronic 
hypertension, but it can only be confirmed after the puerperium, 
although it may take up to 12 weeks post partum.[6] To avoid this, 
all women planning a pregnancy should attend a preconception 
clinic or visit a healthcare professional to exclude diseases such as 
hypertension or diabetes and optimise their disease condition before 
becoming pregnant.[6]
High BP levels in pregnancy are usually regarded as mild (systolic 
140 - 159 mmHg, and/or diastolic 90 - 109 mmHg), or severe (systolic 
>160 mmHg and/or diastolic >110 mmHg).[1] Women with severe 
hypertension are at risk of developing superimposed pre-eclampsia, 
which may occur in up to 30% of cases in the second half of 
pregnancy.[7]
Most patients with chronic hypertension have essential or primary 
hypertension and are treated as having this condition. However, the 
following patients require investigation to exclude secondary causes, 
such as renal disease, collagen vascular and endocrine disorders: 
young women, patients whose high BP levels are difficult to control 
and/or require ≥3 antihypertensive agents, and those whose BP 
levels vary widely. Similarly, women who have been labelled as 
having gestational hypertension, particularly severe hypertension, 
and whose BP levels do not settle 12 weeks post partum, require 
further investigation.
Moreover, in women presenting with chronic hypertension in 
pregnancy, investigations should be done to exclude comorbidities, 
including pregestational diabetes. Box 1 shows the investigations 
required.
In general, initial assessments may help to differentiate between 
low- and high-risk cases of chronic hypertension. The latter would 
Table 1. Clinical characteristics of 40 patients who died owing to chronic hypertension, 2014 - 2016
Clinical characteristics n (%) 
Age (mean 33, range 28 - 45), years
28 - 30 9
31 - 34 9
35 - 39 14
≥40 8
Parity (mean 3, range 0 - 6)
0 4
1 - 3 20
≥4 2
Twin pregnancy (gestational age on admission) (mean 33, range 7 - 36), weeks
<20  8
<20 (with severe hypertension, requiring termination of pregnancy) 3
21 - 33 27
<34  5
Hospital readmission 7
Severe hypertension 3
Pulmonary oedema 2
Respiratory distress 2
Antenatal care
Booked for antenatal care 30 (75)
HIV-positive  18 (45)
HIV unknown 5 (13)
Vaginal delivery 20 (50)
Caesarean delivery 20 (50)
History of chronic hypertension 5 (13)
Obesity 5 (13)
Table 2. Probable preventable factors in maternal deaths due 
to chronic hypertension 
Patient-related factors
Declined admission and/or advice (n=5; 12.5%)
Health professions (medical doctors and professional nurses)-
related factors*
Poor history taking
Poor/incomplete physical examination of patient
Delay in interventions
Delay in obtaining specialist advice 
Timeous referrals
Postnatal care/advice
*All of these preventable factors occurred in combinations.
Box 1. Assessment and investigation
A detailed history and physical examination, including current 
antihypertensive agents, previous surgery and previous pregnancy 
outcomes
A screening glucose tolerance test and/or haemoglobin A1c to 
exclude pregestational diabetes
An echocardiograph to exclude cardiac structural defects, such as 
left ventricular hypertrophy
An electrocardiogram (ECG), particularly in those who have 
had chronic hypertension for >5 years, who previously had 
superimposed pre-eclampsia, and/or who were readmitted for severe 
hypertension and pulmonary oedema during a previous pregnancy 
Proteinuria, either by a spot urine protein:creatinine ratio or a 
24-hour urine proteinuria quantitative test. These are important to 
obtain for a baseline record
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include women with severe hypertension (systolic or diastolic), 
previous pregnancy losses and/or superimposed pre-eclampsia. 
High-risk chronic hypertensive patients should be seen more 
frequently during the antenatal period and advised that they might 
require hospitalisation if they develop superimposed pre-eclampsia. 
Warning signs may be the presence of proteinuria and slight rises in 
BP, especially 5 mmHg increases in diastolic pressure before 20 weeks’ 
gestational age.[8] 
Although some authors divide chronic hypertension in pregnancy 
into low and high risk,[6,7] even low-risk patients have a 10% chance of 
developing superimposed pre-eclampsia and an increased chance of 
abruptio placentae, premature delivery and perinatal death compared 
with normotensive pregnant women; therefore, it may be appropriate 
in the SA setting to obtain specialist advice for all patients, regardless 
of low- or high-risk, and especially when there are cases of comorbid 
disease, such as renal and collagen vascular disease.[9] Prophylactic 
aspirin and supplemental calcium therapies, if started timeously (at 
end of the first trimester), may assist in preventing superimposed 
pre-eclampsia.
There is general consensus in the adult population that long-term 
hypertension is associated with risks, particularly stroke, and that 
long-term BP control decreases the risks of myocardial infarction, 
stroke and renal disease.[10] 
More recently, there has been a call to initiate antihypertensive 
agents at BP levels of 130/80 mmHg if the 10-year risk of a 
cardiovascular event exceeds 10%.[11] 
There is consensus that severe hypertension in pregnancy should 
be treated because of the risk of haemorrhagic stroke.[1] However, 
there is controversy with regard to treatment of mild-to-moderate 
elevations in BP because of exposure of the fetus to antihypertensive 
agents, even if it is over a relatively short period and without any 
evidence of benefit to the mother.[1] This controversy continues,[12] 
despite the Control of Hypertension in Pregnancy Study (CHIPS) 
– a large randomised trial that compared tight control (<85 mmHg 
diastolic BP) with less-tight control (<100 mmHg systolic BP) in 
women with both chronic and gestational hypertension; the primary 
outcomes of the study showed no differences, which included 
superimposed pre-eclampsia, fetal growth restriction, preterm birth 
and abruptio placentae, although the rate of progression to severe 
hypertension was significantly higher in the less-tight group.
 Women with chronic hypertension during pregnancy may present 
in a number of ways:
• If the woman presents in pregnancy and is receiving 
antihypertensive agents, it is best to discontinue these drugs, 
which are contraindicated during pregnancy. Examples include 
angiotensin-converting enzyme inhibitors and angiotensin-
receptor blockers, which are associated with renal and craniofacial 
abnormalities of the fetus.[1] If the BP levels are mildly elevated, 
take a wait-and-see approach, and restart antihypertensives once 
the BP becomes elevated. Methyldopa is probably the drug of 
choice, because it is reported to have no harmful fetal effects, but 
it may not be as effective as labetalol and calcium channel blockers 
(Table 3).
• Women presenting with severe hypertension in pregnancy 
(>160 mmHg systolic BP or >110 mmHg diastolic BP), should 
receive oral antihypertensive treatment (including a rapid-
acting agent) immediately.
• Women presenting with chronic hypertension and/or super-
imposed pre-eclampsia, require additional care that usually 
involves admission to hospital, stabilisation of high BP with 
antihypertensive agents (Table 3), including rapid-acting agents, 
complete laboratory investigations and a management plan, 
including timing of delivery. 
Timing of delivery 
This is usually individualised; inpatients with well-controlled 
hypertension are mostly delivered at 39 weeks’ gestational age.[3] 
Those with superimposed pre-eclampsia are usually delivered by 
the end of the 36th week of pregnancy or earlier, depending on the 
individual case. The decision for delivery should be taken by an 
obstetrician experienced in the management of HDP. 
Postpartum management of chronic 
hypertension 
Women with high-risk hypertension (severe chronic hypertension, 
chronic hypertension with superimposed pre-eclampsia, chronic 
hypertension with multiple antihypertensive agents, chronic 
hypertension that developed to abruptio placentae or comorbid 
disease) should be monitored closely for development of serious 
complications, such as pulmonary oedema, congestive heart failure 
and renal failure.
It should be remembered that because of fluid shifts from the 
extra- to intravascular compartments immediately after pregnancy, 
there are BP elevations in both diastolic and systolic components in 
normotensive and hypertensive women. These incremental rises in 
BP occur mainly in the first 4 days post partum. It is therefore not 
surprising that the International Society for the Study of Hypertension 
in Pregnancy recommends that BP should be monitored closely in all 
high-risk patients with hypertensive disorders for at least 3 days after 
delivery.[3] This is of importance because, in the SA setting, patients 
Table 3. Antihypertensive drugs commonly used in South Africa
Antihypertensive drug Mechanism of action Dose Side-effects
Maintenance agent
Methyldopa a2-receptor 500 - 3 000 mg 2 - 3 × daily Elevation in liver enzymes, depression
Nifedipine, extended release Dihydrapone calcium channel 
blocker
30 - 120 mg orally daily Headache, flushing, reflex tachycardia, 
peripheral oedema, increased liver 
enzymes
Amlodipine Calcium channel blocker 2.5 - 10.0 mg daily As above    
Rapid-acting antihypertensive agents
Labetalol Non-selective β-blocker 20 mg intravenously,
then 40 mg, then 80 mg 
every 10 min 
Maximum dose 300 mg
Bronchospasm 
Do not use in congestive cardiac 
failure
Nifedipine, immediate release Calcium channel blocker 10 mg orally every 20 min 
for 3 doses
Headache, flushing, reflex tachycardia
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with HDP are discharged as soon as possible and are seen after 
delivery at lower levels of healthcare (community clinics), which has 
resulted in a number of cases of maternal deaths due to pulmonary 
oedema and cardiomyopathy in the postpartum period.[4] 
Women with severe chronic hypertension and those with 
superimposed pre-eclampsia must be monitored closely (BP, pulse, 
respiratory rate) and chest radiographs and electrocardiograms 
(ECGs) should be done for at least 72 hours, if not done in the 
antenatal period. 
There may be advantages in using angiotensin-converting enzyme 
inhibitors in the postpartum period, especially if there is a comorbid 
condition such as diabetes or cardiomyopathy. In such cases, 
angiotensin-converting enzyme inhibitors, such as enalapril and 
captopril, have been studied most in pregnancy and have shown to 
be safe during breastfeeding.[12] 
Other antihypertensive agents used during breastfeeding and 
found to be safe are diuretics and beta-blockers, such as labetalol 
and nifedipine. The latter agent is thought to be excellent during 
the postpartum period, given its reno-protective effects, and is the 
preferred first-line agent in the postpartum period. Despite the lack 
of robust studies to direct the choice of antihypertensive agents in the 
postpartum period, a physician’s familiarity with antihypertensive 
agents and the past drug history of the patient should be given 
consideration during drug prescription. There is concern that the use 
of diuretics may reduce intravascular volume and decrease lactation; 
however, their use must be based on the compelling need to use 
diuretics in pulmonary oedema and uncontrolled hypertension in 
pregnancy. The authors, however, prefer a calcium channel blocker 
as a first-line antihypertensive agent. 
Contraceptive advice is of particular importance, given that 
most women with essential chronic hypertension are in the latter 
part of reproductive life. In the SA setting, postpartum insertion of 
an intrauterine contraceptive device prior to discharge should be 
considered, or male and female contraceptive methods discussed 
during the antenatal period, including tubal ligation, as the caesarean 
delivery rate in high-risk chronic hypertension is >50%.[4] 
Summary
• Chronic hypertension has a significant maternal and neonatal 
mortality and morbidity.
• Advice on the management of chronic hypertension in pregnancy 
must be obtained from a specialist or health professional expe-
rienced in the management of HDP.
• Most patients with chronic hypertension who are regarded 
as being at risk, require antihypertensive agents and repeated 
hospitalisations, and are delivered before 37 weeks of pregnancy. 
• Postpartum management of chronic hypertension needs to take 
into account that there are small but important incremental rises 
in systolic and diastolic BP, mainly in the first 3 days post partum.
• Consideration must be given to an appropriate antihypertensive 
agent during breastfeeding.
Case vignette
A 32-year-old patient (parity 3, gravida 4) with a history of chronic 
hypertension was referred by a general medical practitioner to a regional 
hospital. She had initially booked at a community clinic but was not 
referred, despite a history of chronic hypertension and a previous caesarean 
section. She had severe hypertension (BP 160/115 mmHg), proteinuria 
(4+), and was obese. Because her BP was difficult to control, she was 
referred to a tertiary hospital a day later. Prior to referral, magnesium 
sulphate was administered. The patient went into spontaneous labour 
at the tertiary hospital and delivered a stillborn baby (1 400 g). The 
patient was referred back to the regional hospital after 14 days, 
but her BP was not well controlled. She was admitted for 5 days 
for BP control and then discharged, having to return in a month. 
She returned 8 days later with a history of dyspnoea, sweating and 
difficulty with breathing. She was managed in a postnatal ward on a 
combination of antihypertensive agents and died 5 days later.
Comments
There was suboptimal care in the management of this patient:
• At the time of antenatal care booking at the community clinic, 
she gave a history of chronic hypertension and previous caesarean 
section; she was also obese. She should have been referred to 
a regional hospital for a full assessment of her cardiovascular 
system and a screening glucose tolerance test. All patients with 
chronic hypertension in pregnancy must be referred to a higher 
level of care or high-risk clinic for assessment, advice and plan of 
management, including the level of healthcare for further antenatal 
care.
• On referral to the regional hospital, she had severe proteinuric 
hypertension at 32 weeks’ gestation. There was a delay in her 
being seen by a medical doctor. She was administered magnesium 
sulphate and transferred to a tertiary hospital. There were scanty 
notes regarding the exact diagnosis and communication with 
medical staff at the tertiary hospital. This patient probably had 
severe superimposed pre-eclampsia or chronic hypertension, and 
should have been delivered.
• At the tertiary hospital, it appears that although she had severe pre-
eclampsia with a BP that was difficult to control, she was treated 
conservatively. Despite this, she was referred back to the regional 
hospital.  
• The tertiary hospital should have investigated her fully to exclude 
a secondary cause, given the difficulty in controlling her high BP.
• There was no evidence of any investigations for excluding renal/
endocrine/immunological causes of her chronic hypertension or of 
a combined medical physician/obstetrician being consulted.
• There is a need to strengthen inter-facility communication when 
there is referral upstream and downstream.
• There was failure of doctors to recognise worsening of HDP 
(chronic hypertension).
This case illustrates suboptimal care highlighted by the following 
points:
• Patients with chronic hypertension must be referred to a specialist 
or experienced medical officer for advice.
• There is a need to strengthen inter-facility communication when 
patients are referred.
• Uncontrollable hypertension, especially following delivery, requires 
a multidisciplinary team approach to management.
• Superimposed pre-eclampsia or chronic hypertension is a ‘red 
flag’, and a more aggressive approach to timing of delivery must be 
taken. In this case, there was severe hypertension and proteinuria 
at 32 weeks’ gestation. Consideration should have been given to 
delivery. 
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